BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) General Counsel Vincent Paul Liptak purchased 2,500 shares of the company’s stock in a transaction on Friday, August 7th. The shares were bought at an average cost of $15.80 per share, with a total value of $39,500.00. Following the transaction, the general counsel directly owned 109,212 shares of the company’s stock, valued at $1,725,549.60. This represents a 2.34% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Vincent Paul Liptak also recently made the following trade(s):
- On Monday, August 10th, Vincent Paul Liptak purchased 2,200 shares of BlossomHill Therapeutics stock. The stock was bought at an average cost of $16.00 per share, with a total value of $35,200.00.
BlossomHill Therapeutics Trading Down 1.7%
Shares of NASDAQ:BLSM opened at $16.24 on Thursday. BlossomHill Therapeutics, Inc. has a 52-week low of $15.25 and a 52-week high of $17.25.
About BlossomHill Therapeutics
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.
Read More
- Five stocks we like better than BlossomHill Therapeutics
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
